WO2000052046A1 - Immunomodulating glycopeptide - Google Patents
Immunomodulating glycopeptide Download PDFInfo
- Publication number
- WO2000052046A1 WO2000052046A1 PCT/GB2000/000724 GB0000724W WO0052046A1 WO 2000052046 A1 WO2000052046 A1 WO 2000052046A1 GB 0000724 W GB0000724 W GB 0000724W WO 0052046 A1 WO0052046 A1 WO 0052046A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- product
- cell
- proliferation
- assay
- Prior art date
Links
- 102000002068 Glycopeptides Human genes 0.000 title claims abstract description 34
- 108010015899 Glycopeptides Proteins 0.000 title claims abstract description 34
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 title claims abstract description 26
- 230000002519 immonomodulatory effect Effects 0.000 title description 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 129
- 210000004027 cell Anatomy 0.000 claims abstract description 94
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 31
- 201000011510 cancer Diseases 0.000 claims abstract description 16
- 239000002671 adjuvant Substances 0.000 claims abstract description 15
- 238000000338 in vitro Methods 0.000 claims abstract description 13
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 2
- 238000000034 method Methods 0.000 claims description 39
- 238000003556 assay Methods 0.000 claims description 28
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 26
- 241000282414 Homo sapiens Species 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 16
- 230000035755 proliferation Effects 0.000 claims description 15
- 241001465754 Metazoa Species 0.000 claims description 11
- 229960005486 vaccine Drugs 0.000 claims description 11
- 108091008874 T cell receptors Proteins 0.000 claims description 10
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 10
- 230000004936 stimulating effect Effects 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 5
- 238000002560 therapeutic procedure Methods 0.000 claims description 5
- 230000000890 antigenic effect Effects 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 238000002405 diagnostic procedure Methods 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- QCQYVCMYGCHVMR-AAZUGDAUSA-N n-[(2r,3r,4s,5r)-4,5,6-trihydroxy-1-oxo-3-[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexan-2-yl]acetamide Chemical compound CC(=O)N[C@@H](C=O)[C@H]([C@@H](O)[C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O QCQYVCMYGCHVMR-AAZUGDAUSA-N 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 abstract description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 11
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 abstract 1
- 102100034256 Mucin-1 Human genes 0.000 abstract 1
- 239000000047 product Substances 0.000 description 114
- 108090000765 processed proteins & peptides Proteins 0.000 description 38
- 239000000427 antigen Substances 0.000 description 32
- 102000036639 antigens Human genes 0.000 description 32
- 108091007433 antigens Proteins 0.000 description 32
- 230000000638 stimulation Effects 0.000 description 29
- 239000000126 substance Substances 0.000 description 16
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 14
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 14
- 102000043129 MHC class I family Human genes 0.000 description 11
- 108091054437 MHC class I family Proteins 0.000 description 11
- 235000018102 proteins Nutrition 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 230000005867 T cell response Effects 0.000 description 10
- 150000001413 amino acids Chemical group 0.000 description 10
- 108091033319 polynucleotide Proteins 0.000 description 10
- 102000040430 polynucleotide Human genes 0.000 description 10
- 239000002157 polynucleotide Substances 0.000 description 10
- 239000011230 binding agent Substances 0.000 description 9
- 150000001720 carbohydrates Chemical group 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- 230000009870 specific binding Effects 0.000 description 9
- 239000000306 component Substances 0.000 description 8
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 7
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 7
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 7
- 238000001516 cell proliferation assay Methods 0.000 description 7
- 244000052769 pathogen Species 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 229940104230 thymidine Drugs 0.000 description 7
- 229940024606 amino acid Drugs 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000004443 dendritic cell Anatomy 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 230000001717 pathogenic effect Effects 0.000 description 6
- 210000004986 primary T-cell Anatomy 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 102000043131 MHC class II family Human genes 0.000 description 5
- 108091054438 MHC class II family Proteins 0.000 description 5
- 238000004422 calculation algorithm Methods 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 235000000346 sugar Nutrition 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 229920001917 Ficoll Polymers 0.000 description 4
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 4
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 4
- 241000283984 Rodentia Species 0.000 description 4
- 239000002771 cell marker Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000013595 glycosylation Effects 0.000 description 4
- 238000006206 glycosylation reaction Methods 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 3
- OVRNDRQMDRJTHS-KEWYIRBNSA-N N-acetyl-D-galactosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-KEWYIRBNSA-N 0.000 description 3
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 230000001464 adherent effect Effects 0.000 description 3
- 230000030741 antigen processing and presentation Effects 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 230000001186 cumulative effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 210000001165 lymph node Anatomy 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
- 239000001509 sodium citrate Substances 0.000 description 3
- 210000004989 spleen cell Anatomy 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 2
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 2
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 2
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 2
- 101001133081 Homo sapiens Mucin-2 Proteins 0.000 description 2
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 2
- 206010062016 Immunosuppression Diseases 0.000 description 2
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 2
- 102100034263 Mucin-2 Human genes 0.000 description 2
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- -1 at least 20 Chemical class 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 102000003930 C-Type Lectins Human genes 0.000 description 1
- 108090000342 C-Type Lectins Proteins 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 108010039939 Cell Wall Skeleton Proteins 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- RDFLLVCQYHQOBU-GPGGJFNDSA-O Cyanin Natural products O([C@H]1[C@H](O)[C@H](O)[C@H](O)[C@H](CO)O1)c1c(-c2cc(O)c(O)cc2)[o+]c2c(c(O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O3)cc(O)c2)c1 RDFLLVCQYHQOBU-GPGGJFNDSA-O 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102000051366 Glycosyltransferases Human genes 0.000 description 1
- 108700023372 Glycosyltransferases Proteins 0.000 description 1
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 1
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 description 1
- 108010058607 HLA-B Antigens Proteins 0.000 description 1
- 206010066476 Haematological malignancy Diseases 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 1
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 208000007976 Ketosis Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 101100346932 Mus musculus Muc1 gene Proteins 0.000 description 1
- 241000187481 Mycobacterium phlei Species 0.000 description 1
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 1
- 241000237988 Patellidae Species 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- GVUVRRPYYDHHGK-VQVTYTSYSA-N Pro-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1 GVUVRRPYYDHHGK-VQVTYTSYSA-N 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241001222774 Salmonella enterica subsp. enterica serovar Minnesota Species 0.000 description 1
- 108010055044 Tetanus Toxin Proteins 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- LFTYTUAZOPRMMI-NESSUJCYSA-N UDP-N-acetyl-alpha-D-galactosamine Chemical compound O1[C@H](CO)[C@H](O)[C@H](O)[C@@H](NC(=O)C)[C@H]1O[P@](O)(=O)O[P@](O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(NC(=O)C=C2)=O)O1 LFTYTUAZOPRMMI-NESSUJCYSA-N 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 150000001323 aldoses Chemical class 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
- 201000001531 bladder carcinoma Diseases 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 206010006007 bone sarcoma Diseases 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000004520 cell wall skeleton Anatomy 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- RDFLLVCQYHQOBU-ZOTFFYTFSA-O cyanin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=[O+]C1=CC(O)=C2)C=3C=C(O)C(O)=CC=3)=CC1=C2O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 RDFLLVCQYHQOBU-ZOTFFYTFSA-O 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 150000002386 heptoses Chemical class 0.000 description 1
- 150000002402 hexoses Chemical class 0.000 description 1
- 102000046157 human CSF2 Human genes 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 150000002584 ketoses Chemical class 0.000 description 1
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 210000004880 lymph fluid Anatomy 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 210000003810 lymphokine-activated killer cell Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 229940055036 mycobacterium phlei Drugs 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 150000002972 pentoses Chemical class 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940118376 tetanus toxin Drugs 0.000 description 1
- 150000003538 tetroses Chemical class 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 150000004043 trisaccharides Chemical class 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 208000010570 urinary bladder carcinoma Diseases 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 239000012646 vaccine adjuvant Substances 0.000 description 1
- 229940124931 vaccine adjuvant Drugs 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4727—Mucins, e.g. human intestinal mucin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/55—Lung
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Definitions
- the invention relates to a product which causes super-proliferation of T cells for use in a method of treatment or diagnosis; an assay to identify such a product; an ex-vivo cell treated with the product and a vaccine comprising the product and/or the ex-vivo cell.
- the immune system is able to respond to infection by a pathogen or to the development of cancer in an antigen-specific manner.
- Vaccination with appropriate antigens can thus be used to prevent or treat infections and cancer.
- administration of the antigen alone to an individual is often insufficient to cause the development of an effective immune response to the antigen. This is particularly true if the infection or cancer causes immunosuppression.
- Adjuvants are therefore administered with the antigen to increase the magnitude of the immune response produced.
- T cells produced in vitro and specific to the required antigen are administered to the patient.
- this is done by taking T cells from the patient, increasing their number by replication and administering them to the patient.
- replication of T cells in vitro to the required numbers is difficult.
- T cells even antigen naive T cells
- This phenomenon is termed 'super-proliferation' herein.
- a method (described below) for identifying materials which cause such a T cell response has been developed.
- the effects of certain products identified in this manner on T cells responses in vitro has been investigated.
- Products which cause super-proliferation of T cells can be used as vaccine adjuvants or to replicate T cells to high numbers in vitro.
- the products can also be used to produce immune responses which have a specificity towards the product itself, as well as in the detection of T cell responses which may or may not be directed to the product.
- the invention thus provides a product, which product causes super- proliferation of T cells, for use in a method of treatment of the human or animal body by therapy or for use in a diagnostic method practised on the human or animal body.
- the invention also provides a use of the product to treat a cell in vitro.
- the invention provides an ex-vivo cell treated with the product.
- the invention additionally provides a vaccine comprising an antigenic component and, as an adjuvant a product of the invention.
- the product comprises an antigen which is present on the surface of cancer cells, or the product is capable of stimulating T cells which are specific for cancer cells.
- the invention also provides a use of the product in the manufacture of a medicament to prevent or treat cancer.
- Figure 1 shows FACS analysis of A2 stimulated cells.
- A is control
- B is CD19 and C is CD3, CD16/56.
- CD19 is a B cell marker
- CD16 and CD56 are NK markers
- CD3 is a T cell marker.
- Figure 2 shows FACS analyses of cells that proliferate after stimulation with A2 GalNac.
- A is the control
- B is anti-CD4
- C is anti-CD8
- D is anti- ⁇ / ⁇ TCR
- E is anti- ⁇ / ⁇ TCR.
- the vertical axes show counts.
- a product of the invention is generally an individual compound, but can be a composition comprising one or more active compounds which each contribute to causing super-proliferation.
- the product typically comprises at least 5 hydroxyl groups, such as at least 10, 20 or 30 hydroxyl groups.
- the product typically comprises one or more of the modifications which may be present on the peptide discussed below.
- Certain products of the invention are able to bind to one or more different MHC class I or class II molecules.
- the product is able to bind to a receptor on an antigen presenting cell or a T cell, such as a receptor which can bind to glycopeptides.
- the C-type lectin of macrophages is an example of such a receptor (for example as described in reference 1).
- the product can typically be taken up by the antigen presenting cell and be presented on the surface of the cell bound to a MHC class I or class II molecule.
- Certain products of the invention are peptides or comprise a peptide.
- the peptide may comprise sequence from a naturally occurring protein, such as from a human, animal or pathogen, and may thus be a fragment of such a protein.
- the protein is typically one which is glycosylated in nature.
- the protein is one which occurs in a different form in tumour cells, such as having a different pattern of glycosylation in tumour cells.
- the protein is typically one which is expressed on the surface of cells.
- the protein is MUC 1.
- the peptide may comprise amino acid sequence from the repeat sequence of MUCl, such as the sequence N- Ala-His-Gly-Val-Thr-Ser-Ala-Pro-Asp-Thr-Arg-Pro-Ala-Pro-Gly-Ser-Thr-Ala-Pro- Pro-Ala-His-Gly-Val-Thr-Ser-Ala-Pro-Asp-Thr-Arg-Pro-Ala-Pro-Gly-Ser-Thr-Ala- Pro-Pro-Ala-C (SEQ ID NO:2), or a fragment of this sequence.
- a preferred fragment is N-Ala-His-Gly-Val-Thr-Ser-Ala-Pro-Asp-Thr-Arg-Pro-Ala-Pro-Gly-Ser-Thr-Ala- Pro-Pro-Ala-C (SEQ ID NO: l).
- the sequence of the peptide may have homoiogy with any of the peptides mentioned above, such as at least 70% homoiogy, preferably at least 80, 90, 95, 97 or 99% homoiogy, for example over a region of at least 20, preferably at least 30, for instance at least 40, 60 or 100 or more contiguous amino acids.
- Methods of measuring protein homoiogy are well known in the art and it will be understood by those of skill in the art that in the present context, homoiogy is calculated on the basis of amino acid identity (sometimes referred to as "hard homoiogy").
- the UWGCG Package (2) provides the BESTFIT program which can be used to calculate homoiogy (for example used on its default settings).
- the PLLEUP and BLAST algorithms can be used to calculate homoiogy or line up sequences (typically on their default settings), for example as described in Altschul S. F. (1993) J Mol Evol 36:290-300; Altschul, S, F et al (1990) J Mol Biol 215:403- 10.
- HSPs high scoring sequence pair
- Extensions for the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached.
- the BLAST algorithm parameters W, T and X determine the sensitivity and speed of the alignment.
- the BLAST algorithm performs a statistical analysis of the similarity between two sequences; see e.g., Karlin and Altschul (1993) Proc. Natl. Acad. Sci. USA 90- 5873-5787.
- One measure of similarity provided by the BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance.
- P(N) the smallest sum probability
- a sequence is considered similar to another sequence if the smallest sum probability in comparison of the first sequence to the second sequence is less than about 1, preferably less than about 0.1, more preferably less than about 0.01, and most preferably less than about 0.001.
- the homologous peptide typically differs from the original sequence by substitution, insertion or deletion, for example from 1, 2, 3, 4, 5 to 8 or more substitutions, deletions or insertions.
- the substitutions are preferably 'conservative' These are defined according to the following Table. Amino acids in the same block in the second column and preferably in the same line in the third column may be substituted for each other:
- a polynucleotide sequence encoding the homologous peptide typically hybridises with a polynucleotide encoding the original peptide. It typically hybridises at a level significantly above background.
- the signal level generated by the interaction is typically at least 10 fold, preferably at least 100 fold, as intense as 'background' hybridisation.
- the intensity of interaction may be measured, for example, by radiolabelling the probe, e.g. with 32 P.
- Selective hybridisation is typically achieved using conditions of medium to high stringency (for example 0.03M sodium chloride and 0.003M sodium citrate at from about 50°C to about 60°C).
- the peptide (or fragments referred to above) generally has a length of at least 15 amino acids, such as at least 20, 21, 22, 25, 30, 40, 60 or 80 amino acids.
- the peptide is typically modified, such as by a naturally occurring or non-naturally occurring modification.
- the modification may be glycosylation, such as by the addition of 1, 2, 3, 4 or more carbohydrate moieties to the peptide, for example to different amino acids of the peptide.
- the carbohydrate moieties typically comprise natural and/or non-natural sugars which may be present in the form of monosaccharides, disaccharides, trisaccharides or polysaccharides.
- the sugars present in the moieties may be aldoses and/or ketoses.
- the carbohydrate moiety generally comprises a sugar which is a tetrose, pentose, hexose or heptose.
- the sugar is Glu, Gal or GalNac.
- a preferred moiety is Gal-GalNac (Gal ⁇ l- 3GalNac ⁇ ).
- the peptide comprises amino acid sequence from a naturally occurring protein it may also comprise one or more modifications in that sequence which are present in the naturally occurring forms of the protein, such as the patterns of glycosylation.
- the peptide typically comprises less glycosylation than present in the equivalent sequence in the naturally occurring protein, such as less than 80%, 50% or 30%) of the number of sugars present in the naturally occurring sequence.
- the modif ⁇ cation(s) present in the peptide is typically the same as when the protein is present in a non-tumour cell or a tumour cell.
- the carbohydrate moiety is generally attached to a serine, threonine or asparagine residue in the peptide, and is typically O-linked or N-linked to the peptide.
- the moiety is generally attached to the peptide through an ⁇ or ⁇ linkage.
- the modification is typically present on positions 10 and/or 17, (i.e. the tenth and seventeenth residues respectively from the N terminal of the peptide), or the equivalent positions in a homologous peptide.
- a preferred product comprises a glycopeptide with the amino acid sequence of SEQ ID NO: 1 which has a Gal-GalNac (Gal ⁇ l-3GalNac ⁇ ) or GalNac (N-acetyl galactosamine ⁇ ) moiety on Thr at position 10 or Thr at position 17.
- This glycopeptide is referred to as the ' 10, 17 glycopeptide' herein.
- the product is peptide A2, A2 GalNac or A3 as shown in Table 2.
- Certain products are able to bind to a specific binding agent of the 10, 17 glycopeptide.
- Such a specific binding agent may be the receptor on T cells which the 10, 17 glycopeptide binds to in order to cause super-proliferation in the assay described below.
- the specific binding agent may be an antibody specific to the 10, 17 glycopeptide. Such an antibody can be produced by routine methods, such as those described below.
- the specific binding agent will generally be able to inhibit super-proliferation caused by the 10, 17 glycopeptide in the assay described below. Products able to bind to a specific binding agent of the 10, 17 glycopeptide can generally compete with the 10, 17 glycopeptide in binding to the specific binding agent or to T cells, and therefore will inhibit the binding of the 10, 17 glycopeptide to the specific binding agent or to T cells.
- the product of the invention may or may not include peptides comprising sequence from the tandem repeat of MUCl (such as SEQ LD NO:l or SEQ ID NO:2; or a fragment thereof) which have GalNac or GalNac-sialic acid attached to (i) the Thr of the Gly-Val-Thr-Ser-Ala motif, or (ii) the Ser and/or Thr of the Gly-Ser-Thr- Ala-Pro motif.
- MUCl such as SEQ LD NO:l or SEQ ID NO:2; or a fragment thereof
- a product according to the invention which causes super-proliferation of T cells is one which gives a stimulation index of at least 10 or more when used in the assay described below.
- the product may thus give a stimulation index of at least 15, 20, 30, 50, 80, 100, 200 or more in this assay.
- Peripheral blood lymphocytes are prepared from 20ml of blood from a healthy human donor. The buffy coat containing the PBL is separated from the other blood components by centrifuging using a Ficoll gradient. PBL separated in this way will contain antigen presenting cells. 2 x 10 5 PBL are added to a well of a 96 well plate in 200 ⁇ l of ATM V medium and 50 ⁇ g/ml of the candidate substance (the ATM V medium used is typically Cat. No. 12030-011 from GLBCO BRL). A control well is set up in the same way but does not contain the candidate substance. The well is incubated for 96 hours at 37°C.
- l ⁇ Ci of 3 H thymidine is then added to the well and a further incubation for 18 hours at 37 °C is performed.
- the cells are harvested and the incorporation of thymidine is determined.
- the stimulation index is calculated by dividing the average counts obtained for the candidate substance by the average counts obtained for the cells in the control well.
- the super-proliferation is inhibited by antibodies which bind to MHC class I molecules and/or antibodies which bind to MHC class II molecules, such as W632 antibody which binds class I molecules or Tal 3c3 which binds class II molecules.
- the product typically causes super-proliferation of any of the T cells described below which can be treated with the product, for example at a concentration of 50 ⁇ g/ml.
- Products according to the invention cause super-proliferation in the assay described above. They may or may not cause super-proliferation of T cells in vivo or of T cells which are different to the T cells used in the assay. However, in general, the products of the invention will cause super-proliferation of other T cells or super- proliferation of T cells in conditions other than those of the assay.
- the inventors have shown that when rodent cells (such as mouse or rat cells) are treated with certain products of the invention these cells do not undergo super- proliferation. Thus the product may or may not be able to cause super-proliferation of T cells of rodents. Thus if products which do not cause super-proliferation of rodent T cells are used (with rodent T cells) in the assay described above then generally the stimulation index will be less than 10, for example less than 8, 6, 4, 2 or 1.
- the product of the invention may be produced by conventional techniques well known to those skilled in the relevant arts.
- Peptides may be synthesised de novo or produced by transcription and translation of DNA or translation of RNA in a suitable expression system by conventional methods.
- Products which are new chemical compounds may be produced by known techniques of synthetic organic chemistry.
- Methods of making glycopeptides are known in the art (3).
- the carbohydrate side-chains can typically be added to the glycopeptide using the relevant glycosyl transferase(s).
- the carbohydrate side-chain is built up on the peptide by step-wise addition of saccharide units.
- the term 'stimulation' refers to causing the T cell to become activated after the contact of a receptor on the surface of the T cell with the product.
- the activation may be include the differentiation and/or proliferation of the T cell.
- the activation may cause the T cell to begin to secrete or increase its secretion of cytokines.
- the stimulation may be antigen specific or non-specific. When it is non-specific different T-cells carrying T-cell receptors specific to different antigens will be stimulated to proliferate. Thus the stimulated T-cells may be monoclonal or polyclonal.
- Certain products are presented to the T cell on a MHC class I or II molecule.
- the stimulation may be specific or non-specific with regards to the MHC class I or II molecules which present the product to the T cell.
- the proliferation which occurs upon stimulation may be super-proliferation.
- the stimulation may be of primary (antigen naive) T cells or secondary
- T cells (antigen experienced) T cells.
- Primary T cells have not been previously exposed to the antigen which is recognised by the T cell receptor which they carry.
- Secondary T cells are formed from primary T cells by replication of the primary T cell in response to exposure to an antigen which is recognised by the T cell receptor.
- the T cells will be CD4 or CD8 positive. In one embodiment the T cell will recognise the product in a MHC class II or class I restricted manner.
- the CD4 T cell may be a Thl or Th2 type cell, Thl being preferred.
- the T cell may be a cytotoxic T cell.
- the T cell may be a lymphokine-activated killer (LAK) cell.
- LAK lymphokine-activated killer
- the production of LAK cells is known in the art (8). These cells are generally produced by treating peripheral blood lymphocytes with LL-2.
- the T cell may be a tumour infiltrating lymphocyte (TIL). TIL can be produced by culturing a dissociated tumour in LL-2 and then separating the differentiated lymphoblasts which are produced. One method of producing TLL is described below.
- the T cell may be derived from a lymph node which drains a tumour.
- the T cells may carry a T cell receptor which is specific to an antigen from a pathogen, such as a virus, bacterium or fungus.
- the T cell receptor may be specific to a cancer antigen, for example an antigen which is produced by cells of any of the cancers mentioned below.
- the invention provides the use of the product to treat a cell in vitro.
- the cell is treated in a method comprising contacting the cell with the product.
- the product is present at a concentration of at least 0.1 ⁇ g/ml, such as (e.g. at least or about) 1 ⁇ g/ml, lO ⁇ g/ml, 50 ⁇ g/ml, lOO ⁇ g/ml, lOOO ⁇ g/ml or more.
- the cell is typically contacted with the product for at least 0.5 hours, such as (e.g.
- the cell which is treated is generally a T cell as described above or an antigen presenting cell.
- the product may be used to treat a population of cells comprising T cells and antigen presenting cells (for example present in the amounts described below for composition of the invention).
- the cells which are to be treated are generally derived from a human or animal.
- the cells may be from an individual who is healthy, who may or may not be at risk from a disease.
- the individual may have a disease.
- the cells may be derived from the blood or from the vicinity of a tumour, or may be cells which have infiltrated a tumour.
- the cells may be from the lymphatic system, such as from a lymph node.
- the lymph node may be one which receives lymph fluid from a tumour.
- the product will generally cause stimulation of the T cells.
- the stimulation may cause super-proliferation, and thus the invention provides a method of causing super-proliferation of a T cell comprising contacting the product with a T cell.
- antigen presenting cells will also be present during stimulation of T cells, and these may present the product to the T cell, for example bound to a MHC class I or LI molecule. Certain products are capable of stimulating the T cells in the absence of antigen presenting cells.
- the T cells may be additionally treated with other agents.
- agents may enhance the stimulation caused by the product or may cause only specific T cells to be stimulated.
- agents include cytokines, such as LL-2 or LL-7; adjuvants, such as keyhole limpet cyanin or any of the other adjuvants mentioned herein; or antigens which are recognised by the T cells.
- cytokines such as LL-2 or LL-7
- adjuvants such as keyhole limpet cyanin or any of the other adjuvants mentioned herein
- antigens which are recognised by the T cells.
- the agents may also include other cells, such as CD4 T cells in the case where CD 8 T cells are being stimulated.
- the stimulation of the T cells may be under conditions where the T cells proliferate in response to the stimulation.
- the method can be used to 'grow up' (i.e. increase the numbers of) T cells which have been taken from an individual.
- the T cells which are stimulated may be primary T cells, and thus the method of the invention can be used to produce a primary T cell response in vitro, i.e. to cause proliferation of primary T cells to the extent that they are detectable in proliferation or cytotoxic assays.
- Reference 9 shows for example how such assays may be performed.
- the method may be used to detect particular T cells, such as T cells specific for a particular antigen.
- T cells specific for a particular antigen proliferation of the T cells, secretion of substances from the T cell or killing of target cells by the T cell; in response to the antigen is used as the basis of a detection assay.
- detection assays are limited in their sensitivity of detection of the T cells and are unable to detect T cells present at low concentrations.
- the product of the invention can be used to cause proliferation of such T cells to aid their detection in such assays.
- the antigen which the T cells recognise may be the product itself.
- the method of the invention can be used to detect T cells specific to the product.
- the method may also be used to detect T cells which are not specific for the product.
- the antigen which the T cells are specific for will also be provided to the T cells.
- the method of the invention may be used to detect this T cell response and thus can be used in the diagnosis of the disease.
- a disease may be one which causes immunosuppression.
- the disease may be caused by a pathogen or a tumour, such as any of the cancers discussed below.
- the T cells taken from an individual with a disease which are to be stimulated in the method will be secondary T cells. These T cells will be specific for antigens produced by the entity causing the disease. Such an entity will generally be a pathogen or a tumour.
- the antigen presenting cell which is treated in the method of the invention may be a cell which naturally acts as a professional antigen presenting cell or a may be non-natural antigen presenting cell which is able to present the product to the T cell.
- the antigen presenting cell is typically a dendritic cell, monocyte, macrophage or B cell.
- the antigen presenting cell may be the Drosophila cell described in WO 93/17095 which is capable of antigen presentation, CHO cells, baculovirus infected insect cells, bacteria, yeast or vaccinia-infected cells.
- the antigen presentation system may be based on (10).
- the dendritic cell has been cultured ex vivo from CD34+ stem cells or CD 14+ peripheral blood monocytes, for example using GM-CSF, LL-4 and TNF- ⁇ .
- the antigen presenting cell may be treated with the product in order to present the product in a suitable context to the T cell, such as bound to MHC class I or class LI molecules.
- the treatment of the antigen presenting cell generally makes it capable of stimulating a T cell able to recognise the antigen.
- the cell which is treated may be a cell which presents empty MHC class I or II molecules on its surface. Such a cell may be defective in MHC presentation.
- the cell which is treated may be a T2 cell.
- the ex-vivo cell of the invention is generally a T cell which has been stimulated by the product or an antigen presenting cell which has been provided with the product. Such cells can be made in the method of the invention.
- the stimulation of the T cell may or may not be antigen specific, and therefore the T cell may or may not have a T cell receptor which recognises the product.
- the T cell may be present in a polyclonal or monoclonal population of T cells.
- the T cell of the invention may have any of the characteristics of the T cells described above.
- the antigen presenting cell of the invention carries the product on its surface in conjunction with an MHC class I or class LI molecule.
- the antigen presenting cell has at least 200, for example at least or about 500 or 1000, class I or class LI molecules on its surface loaded with the product.
- the cells of the invention may be labelled or may carry a label, such as labelled thymidine or radioactive chromium.
- the invention also provides a composition comprising T cells, antigen presenting cells and a product of the invention.
- the T cells or antigen presenting cells may be any of the cells mentioned above.
- the T cell: antigen presenting cell ratio is typically from 500: 1 to 1 :500.
- at least 10 3 such as (e.g. at least or about) 10 3 , 10 6 , 10 7 , 10 8 , 10 9 cells are present per millilitre of the composition.
- the composition typically also comprises a culture medium capable of supporting the T cells or antigen presenting cells, such as RPMI medium.
- the medium may also comprise cytokines, such as LL-2, LL-4, LL-7 or TNF- ⁇ .
- the T cells and antigen presenting cells may be from the same individual.
- the composition may comprise a mononuclear cell fraction, for example which has been separated from peripheral blood.
- the product may act as an antigen and/or as an adjuvant.
- the product acts as an antigen if the vaccine leads to the stimulation of T cells which carry a receptor specific for the product.
- the product acts as an adjuvant if the vaccine leads to the stimulation of T cells which do not carry a T cell receptor which is specific for the product.
- the product may act as an antigen or adjuvant in a manner that is dependent on or independent of the MHC class I or LI type of the individual to whom the vaccine is administered.
- the antigenic component may be from a pathogen or a cancer, such as the pathogens or cancers discussed herein.
- the adjuvant component may be one which favours the development of a T cell response (for example a CD4 or CD8 T cell response) over an antibody response, such as of any of the T cells discussed above.
- the adjuvant component may comprise a cytokine such as LL-2 or LL-7, keyhole limpet hemocyanin, tetanus toxin or LAMPI (e.g. as described in (12)).
- the adjuvant may comprise an oil droplet emulsion, squalene, or components of bacteria, such as Mycobacterium phlei (e.g. cell wall skeleton) or Salmonella minnesota (e.g. menophosphoryl lipid A).
- the adjuvant may be DetoxTM.
- the adjuvant is a liposome, for example as in (11).
- the product may be linked to a substance which directs it to the MHC class I or LI pathway, such as a tat peptide, for example as in (13).
- a tat peptide for example as in (13).
- the antibodies may be specific for the product.
- the vaccine contains an antigenic component which is not the product the antibodies may be specific for such a component.
- the cells of the invention may also be used in a method of treatment of the human or animal body by therapy.
- the cells may be administered to a patient.
- the cells which are administered may be autologous cells, or cells which have been partially or fully matched with the patient for MHC class I HLA-A or HLA-B; or for MHC class II type.
- the cells may be present in or derived from the composition of the invention discussed above.
- the cells may be separated from the composition using a specific binding agent which binds either the cell to be administered to the patient or the other cells in the composition which need to be removed.
- the specific binding agent is an antibody.
- the invention also provides an assay for identifying a product which causes super-proliferation of T cells comprising contacting a compound or composition with a T cell and determining whether the T cell undergoes super-proliferation.
- the assay is typically the assay described above.
- the assay may thus be used to screen candidate substances.
- candidate substances may be present in extracts from human or animal cells, such as extracts from tumour cells.
- the candidate substances may be present in combinatorial libraries or natural product libraries, such as phage display libraries.
- the assay may also be used to design products of the invention.
- the invention provides a product which causes super-proliferation of T cells and which is not described in a database at the date of filing of the application. Such a product is thus not known in the art at the date filing of the application.
- the product of the invention may be provided in a kit for causing super- proliferation of T cells.
- a kit may be for replicating cells in vitro prior to administering them to a patient (as described above for the method of causing super- proliferation of a T cell).
- the kit may be for diagnosing cancer, in which case the produce is used to detect the presence of cancer specific T cells (such as T cells specific for the product), for example as described above for the detection of T cell responses.
- the product or cell of the invention may be present in a substantially isolated form. It will be understood that the product or cell may be mixed with carriers or diluents which will not interfere with the intended purpose of the product or cell and still be regarded as substantially isolated.
- the product may be in substantially purified form in which case it will generally comprise more than 90%, (e.g. more than, at least or about) 95, 98 or 99%> of dry mass in a preparation; or if the product is a peptide it may comprise more than 90%*, (e.g. more than, at least or about) 95, 98 or 99%o of the peptide in the preparation.
- the cell may be in a substantially purified form in which case it will generally comprise more than 90%>, (e.g. more than, at least or about) 95, 98, or 99%o of the cells or dry mass in the preparation.
- the invention also provides a method of diagnosing or treating a disease by administering an effective non-toxic amount of a product or cell of the invention to a human or non-human animal in need thereof.
- the disease may be cancer, and thus the method may diagnose or treat carcinomas, for example mammary carcinoma, lung carcinoma, bladder carcinoma, colon carcinoma, ovary and endometrial tumours.
- Other cancers which may be diagnosed or treated include sarcomas, such as soft tissue and bone sarcomas, and haematological malignancies, such as leukemias.
- the product or cell of the invention may be formulated for clinical administration by mixing them a pharmaceutically acceptable carrier or diluent.
- a pharmaceutically acceptable carrier or diluent for example the product or cell may be formulated for topical, parenteral, intravenous, intramuscular, subcutaneous or transdermal administration. They may be mixed with any vehicle, for example a diluent or carrier which is pharmaceutically acceptable and appropriate for the desired route of administration.
- the pharmaceutical carrier or diluent for injection may be, for example, a sterile or isotonic solution such as Water for Injection or physiological saline.
- the dose may be adjusted to deliver an effective non-toxic amount and according to various parameters, especially according to the nature and efficacy of the substance used; the age, weight and condition of the patient to be treated; the mode of administration used; the conditions to be treated; and the required clinical regimen.
- the amount of the product of the invention to be administered by injection will generally be from 10 to lOOO ⁇ g. For instance 100 to 500 ⁇ g.
- the number of cells of the invention to be administered will generally be from 10 5 to 10 13 , preferably from 10 7 to 10 n .
- cells are administered in a solution with a volume of at least 20ml, for example at least 50ml, 100ml, 200ml or more.
- the cells can be given to the patient in 1, 2, 3, 10, 20 or more separate administrations, each administration separated, for example, by at least 1 hour, 2 hours, 5 hours, 12 hours, 1 day, 2 days, 4 days, 7 days, 1 month or more.
- Administration regimens for TLL are described in (4).
- Antibodies can be made to any of the substances mentioned herein, for example as described in (7).
- the antibodies may be purified or isolated, for example to any of the levels of purification discussed above for the product of the invention.
- TLL can be obtained by digesting a tumour in a collagenase, DNAse type I and hyaluronidase type V enzyme mixture, filtering the resulting suspension (e.g. using a wire mesh), and separating the lymphocytes from the filtrate using a Ficoll gradient.
- the TLL can be cultured at a density of 5 x 10 5 viable cells/ml in ALMN (or RPMI supplemented with 10% human serum), 6000 IU/ml of LL-2 and lOOOU/ml of LL-4 at 37° C with 5% CO 2 .
- ALMN or RPMI supplemented with 10% human serum
- 6000 IU/ml of LL-2 and lOOOU/ml of LL-4 at 37° C with 5% CO 2 .
- the culture can be divided and diluted.
- Certain substances may provide the product of the invention when they are administered to an individual or when they are contacted with (e.g. provided inside) mammalian cells, e.g. any of the cells mentioned herein. Such substances are included in the term 'product' used herein. Thus such substances can be used in the in vivo and in vitro methods discussed herein and can be administered in the same way as described for administration of the product.
- the substance is typically a precursor of the product which can be processed (typically hydrolysed) by cells to provide the product.
- processing may modify the peptide and/or carbohydrate component.
- the precursor may for example be capable of being processed in the antigen processing pathways of any of the antigen presenting cells mentioned herein.
- the precursor may comprise the product with additional sequence at the ⁇ and/or C terminal of the product.
- the substance is a polynucleotide which is capable of being expressed to provide the product (or precursor discussed above).
- the polynucleotide is typically D ⁇ A or R ⁇ A, and is single or double stranded.
- the polynucleotide generally comprises sequence that encodes the peptide.
- the coding sequence is typically operably linked to a control sequence capable of providing for expression of the polynucleotide.
- the polynucleotide comprises 5' and 3' to the coding sequence sequences which aid expression, such as aiding transcription and/or translation of the coding sequence.
- the polynucleotide is typically capable of expressing the product in a mammalian cell, such as in a human cell.
- the polynucleotide may be capable of expressing the product in the cellular vector discussed below.
- the polynucleotide is present in a virus or cellular vector, such as a virus which is capable of stimulating a CD8 T cell response, such as a vaccinia virus (e.g. MNA or ⁇ NVAC).
- a virus or cellular vector such as a virus which is capable of stimulating a CD8 T cell response, such as a vaccinia virus (e.g. MNA or ⁇ NVAC).
- a vaccinia virus e.g. MNA or ⁇ NVAC
- blood collection tubes containing 20ml RPMI, sodium citrate and mercaptoethanol
- the tubes are spun at 400g for 20 minutes and the buffy coat containing the PBLs removed and washed three times with Hanks buffered salt solution and once in ALMN medium.
- Antigen presenting cells are present in the preparation.
- 20-25ml of blood is taken into blood collection tubes containing 20ml of RPMI, sodium citrate and mercaptoethanol and layered onto Ficoll.
- the tubes are spun at 400g for 20 minutes and the buffy coat containing the PBLs removed and washed three times with Hanks buffered salt solution (9) and once in ALMN medium.
- Between 5 and 20 x 10 6 cells are plated onto 33mm culture dishes in AIMN and cells allowed to adhere for 2 hours.
- the non-adherent cells are gently removed and the adherent cells cultured in ALMN medium containing 500 units/ml human LL- 4 and 800 units/ml of human GM-CSF. 1ml of medium is removed every 2-3 days and replaced with fresh medium containing cytokines LL 4 and GM-CSF.
- the dendritic cells are ready to be used as APCs.
- Dendritic cells cultured for 7 days as described above are harvested by pipetting and divided among an appropriate number of tubes (3 x 33mm dishes between 5 or so tubes, 15ml Falcons). The cells are spun and taken up in 1ml ALMN medium and incubated for 2 hours at 37°C with 20-100 ⁇ g/ml of the glycopeptide or buffer alone.
- the stimulation index is calculated by dividing the average counts obtained for the test glycopeptide by the average counts obtained for the cells with buffer alone. This is a standard way of presenting this type of data and it is generally thought that for a sample to be considered positive it must give a stimulation index of 3 or over.
- Results from proliferation assays are shown in Table 1.
- the glycopeptides tested are shown in Table 2 (they are Linked to the peptide through an ⁇ linkage). AlO is the same as A9 but with a Lys at the ⁇ -terminal of the A9 sequence.
- Table 1 shows results with T cells from 7 healthy donors (left hand 7 columns) and 6 breast cancer patients (BrCa).
- Example 3 Proliferation assay using CD4 T cells 50 ⁇ g/ml of glycopeptide was added to 2 x 10 5 CD4 T cells per well ( in a flat bottomed 96 well plate).
- GalNAc O GalNAc Ala-His-Gly-Val-Thr-Ser-Ala-Pro-Asp-Thr-Arg-Pro-Ala-Pro-Gly-Ser-Thr-Ala-Pro-Pro-Ala
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002363957A CA2363957A1 (en) | 1999-03-01 | 2000-03-01 | Immunomodulating glycopeptide |
EP00906521A EP1157036A1 (en) | 1999-03-01 | 2000-03-01 | Immunomodulating glycopeptide |
JP2000602270A JP2002542156A (en) | 1999-03-01 | 2000-03-01 | Immunomodulatory glycopeptide |
AU28180/00A AU2818000A (en) | 1999-03-01 | 2000-03-01 | Immunomodulating glycopeptide |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9904695.5 | 1999-03-01 | ||
GBGB9904695.5A GB9904695D0 (en) | 1999-03-01 | 1999-03-01 | Peptide |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000052046A1 true WO2000052046A1 (en) | 2000-09-08 |
Family
ID=10848737
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2000/000724 WO2000052046A1 (en) | 1999-03-01 | 2000-03-01 | Immunomodulating glycopeptide |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1157036A1 (en) |
JP (1) | JP2002542156A (en) |
AU (1) | AU2818000A (en) |
CA (1) | CA2363957A1 (en) |
GB (1) | GB9904695D0 (en) |
WO (1) | WO2000052046A1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001070265A2 (en) * | 2000-03-24 | 2001-09-27 | Biomira, Inc. | Lipopeptide adjuvants |
WO2009108807A1 (en) * | 2008-02-26 | 2009-09-03 | The Regents Of The University Of California | Glycopeptides and methods of making and using them |
EP1343814B1 (en) * | 2000-12-21 | 2009-09-16 | Institut Pasteur | Immunogenic glycopeptides, screening, preparation and uses |
US8648172B2 (en) | 2005-01-28 | 2014-02-11 | Biomodifying, Llc | Anti-MUC1 α/β antibodies |
US9528088B2 (en) | 2002-06-28 | 2016-12-27 | Life Technologies Corporation | Methods for eliminating at least a substantial portion of a clonal antigen-specific memory T cell subpopulation |
US11793886B2 (en) | 2017-06-21 | 2023-10-24 | Glykos Finland Oy | Hydrophilic linkers and conjugates thereof |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1989008711A1 (en) * | 1988-03-11 | 1989-09-21 | The Biomembrane Institute | Monoclonal antibodies and vaccine development directed to human cancer-associated antigens by immunization with animal and human mucin and with synthetic carbohydrate-carrier conjugates |
WO1992001055A1 (en) * | 1990-07-10 | 1992-01-23 | Boehringer Ingelheim International Gmbh | O-glycosylated ifn-alpha |
WO1995003825A1 (en) * | 1993-07-30 | 1995-02-09 | Finn Olivera J | Synthetic multiple tandem repeat mucin and mucin-like peptides, and uses thereof |
GB2288401A (en) * | 1994-04-15 | 1995-10-18 | Bay Dev Corp Sa | N-acetylgalactosaminyltransferase |
WO1996007753A1 (en) * | 1994-09-06 | 1996-03-14 | Bioflexin Ab | Amino acid conjugate |
WO1996022067A2 (en) * | 1994-12-27 | 1996-07-25 | United Biomedical, Inc. | Peptide ratchet libraries for ctl-inducing vaccines and therapeutics |
EP0754703A1 (en) * | 1994-11-01 | 1997-01-22 | Kirin Beer Kabushiki Kaisha | Peptide sequence that forms mucin sugar chain and technique for modifying protein to be linked with mucin sugar chain |
WO1997034921A1 (en) * | 1996-03-20 | 1997-09-25 | Sloan-Kettering Institute For Cancer Research | Conjugated mucin peptide vaccines |
WO1998017300A1 (en) * | 1996-10-25 | 1998-04-30 | Dana-Farber Cancer Institute, Inc. | Mucin-mediated immunomodulation |
DE19758400A1 (en) * | 1997-12-30 | 1999-07-01 | Max Delbrueck Centrum | Tumor vaccine for MUC1-positive carcinomas |
-
1999
- 1999-03-01 GB GBGB9904695.5A patent/GB9904695D0/en not_active Ceased
-
2000
- 2000-03-01 AU AU28180/00A patent/AU2818000A/en not_active Abandoned
- 2000-03-01 JP JP2000602270A patent/JP2002542156A/en active Pending
- 2000-03-01 EP EP00906521A patent/EP1157036A1/en not_active Withdrawn
- 2000-03-01 CA CA002363957A patent/CA2363957A1/en not_active Abandoned
- 2000-03-01 WO PCT/GB2000/000724 patent/WO2000052046A1/en not_active Application Discontinuation
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1989008711A1 (en) * | 1988-03-11 | 1989-09-21 | The Biomembrane Institute | Monoclonal antibodies and vaccine development directed to human cancer-associated antigens by immunization with animal and human mucin and with synthetic carbohydrate-carrier conjugates |
WO1992001055A1 (en) * | 1990-07-10 | 1992-01-23 | Boehringer Ingelheim International Gmbh | O-glycosylated ifn-alpha |
WO1995003825A1 (en) * | 1993-07-30 | 1995-02-09 | Finn Olivera J | Synthetic multiple tandem repeat mucin and mucin-like peptides, and uses thereof |
GB2288401A (en) * | 1994-04-15 | 1995-10-18 | Bay Dev Corp Sa | N-acetylgalactosaminyltransferase |
WO1996007753A1 (en) * | 1994-09-06 | 1996-03-14 | Bioflexin Ab | Amino acid conjugate |
EP0754703A1 (en) * | 1994-11-01 | 1997-01-22 | Kirin Beer Kabushiki Kaisha | Peptide sequence that forms mucin sugar chain and technique for modifying protein to be linked with mucin sugar chain |
WO1996022067A2 (en) * | 1994-12-27 | 1996-07-25 | United Biomedical, Inc. | Peptide ratchet libraries for ctl-inducing vaccines and therapeutics |
WO1997034921A1 (en) * | 1996-03-20 | 1997-09-25 | Sloan-Kettering Institute For Cancer Research | Conjugated mucin peptide vaccines |
WO1998017300A1 (en) * | 1996-10-25 | 1998-04-30 | Dana-Farber Cancer Institute, Inc. | Mucin-mediated immunomodulation |
DE19758400A1 (en) * | 1997-12-30 | 1999-07-01 | Max Delbrueck Centrum | Tumor vaccine for MUC1-positive carcinomas |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001070265A2 (en) * | 2000-03-24 | 2001-09-27 | Biomira, Inc. | Lipopeptide adjuvants |
WO2001070265A3 (en) * | 2000-03-24 | 2002-07-04 | Biomira Inc | Lipopeptide adjuvants |
EP1343814B1 (en) * | 2000-12-21 | 2009-09-16 | Institut Pasteur | Immunogenic glycopeptides, screening, preparation and uses |
US9528088B2 (en) | 2002-06-28 | 2016-12-27 | Life Technologies Corporation | Methods for eliminating at least a substantial portion of a clonal antigen-specific memory T cell subpopulation |
US8648172B2 (en) | 2005-01-28 | 2014-02-11 | Biomodifying, Llc | Anti-MUC1 α/β antibodies |
WO2009108807A1 (en) * | 2008-02-26 | 2009-09-03 | The Regents Of The University Of California | Glycopeptides and methods of making and using them |
EP2250189A1 (en) * | 2008-02-26 | 2010-11-17 | The Regents of the University of California | Glycopeptides and methods of making and using them |
EP2250189A4 (en) * | 2008-02-26 | 2012-07-04 | Univ California | Glycopeptides and methods of making and using them |
US9156906B2 (en) | 2008-02-26 | 2015-10-13 | The Regents Of The University Of California | Glycopeptides and methods of making and using them |
US11793886B2 (en) | 2017-06-21 | 2023-10-24 | Glykos Finland Oy | Hydrophilic linkers and conjugates thereof |
Also Published As
Publication number | Publication date |
---|---|
CA2363957A1 (en) | 2000-09-08 |
GB9904695D0 (en) | 1999-04-21 |
AU2818000A (en) | 2000-09-21 |
EP1157036A1 (en) | 2001-11-28 |
JP2002542156A (en) | 2002-12-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Takahashi et al. | Evidence for immunologic immaturity of cord blood T cells. Cord blood T cells are susceptible to tolerance induction to in vitro stimulation with a superantigen. | |
US20140023670A1 (en) | Cancer vaccine composition | |
KR20100063060A (en) | Cdca1 peptide and pharmaceutical agent comprising the same | |
TWI572718B (en) | Immunosuppressive cells and making methods and composition thereof | |
JPWO2014098012A1 (en) | Method for activating helper T cells | |
EP2881462B1 (en) | Method for obtaining monocytes or nk cells | |
CN111593022B (en) | vMIP-II induced CD8+ T cell dephosphorylation to Tcm and its application in medicine | |
US8153120B2 (en) | Methods for inducing a natural killer (NK) cell-mediated immune response and for increasing NK cell activity | |
US7659084B2 (en) | Methods for detecting and isolating antigen-specific T lymphocytes with CD40/C154 inhibitors | |
EP1157036A1 (en) | Immunomodulating glycopeptide | |
Jesudason et al. | Non-human primate dendritic cells | |
WO2011038689A1 (en) | Novel human cytokine vstm1-v2 and use thereof | |
US20090131346A1 (en) | Antibody and method for identification of dendritic cells | |
WO2017009349A1 (en) | Histone anti-cancer vaccines | |
Drakes et al. | Inverse relationship between dendritic cell CCR9 expression and maturation state | |
US20210401885A1 (en) | Cancer antigen specific cytotoxic t cell | |
CN115094034A (en) | Human NKT cell line and application thereof | |
US20030165479A1 (en) | Methods for isolating proteins expressed by dendritic cells | |
CN110585427B (en) | Composition for improving immunity of organism and application of composition in resisting adult T cell leukemia or nasopharyngeal carcinoma | |
KR101264811B1 (en) | Maturation method for Dendritic cell using Mycobacterium abscessus MAB0981c | |
CN108441473A (en) | A kind of method of ex vivo enrichment CD8+* T cells | |
Guo et al. | Dendritic cells modified by tumor associated antigen SMP30 have enhanced antitumor effect against mouse hepatocarcinoma cells in vitro and in vivo | |
CN114645022B (en) | CD 5-targeted CAR-gamma delta T cell and preparation method and application thereof | |
CN112675201B (en) | Application of macrophage subgroup and regulator thereof in acute graft-versus-host disease | |
Jia et al. | Regulation roles of MICA and NKG2D in human renal cancer cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 602270 Kind code of ref document: A Format of ref document f/p: F |
|
ENP | Entry into the national phase |
Ref document number: 2363957 Country of ref document: CA Ref country code: CA Ref document number: 2363957 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 28180/00 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000906521 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2000906521 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09914772 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000906521 Country of ref document: EP |